Open access
Sep 2026
A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
In this phase I, first-in-human phase I study, PF-07062119 monotherapy demonstrated a generally tolerable safety profile within the context of this early-phase study with evidence of clinical activity in patients with advanced/metastatic GI cancers.
M. Fakih, Toshihiko Doi, A. Tolcher et al.
· Cancer Research Communicatio... · 0 citations